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Bladder cancer is one of the most common malignant diseases in the
urinary system and a highly aggressive neoplasm. The prognosis is not
favorable usually and its evolution for particular patients is very difficult
to find out. In this paper, we propose a dynamic mathematical model that
describes the bladder tumor growth and the immune response evolution.
This model is customized for a single patient, determining appropriate
model parameter values via model calibration. Due to the uncertainty
of the tumor evolution, using the calibrated model parameters, we pre-
dict the tumor size and the immune response evolution over the next few
months assuming three different scenarios: favorable, neutral and unfa-
vorable. In the former, it is not expected any trace of the cancer in the
middle of September 2018 (after 16 months). In the neutral scenario, at
the same date, a 7-8 mm tumor is expected. In the worst case, a 40 mm
tumor is expected. The patient was cited on September 10th, 2018, to
check the tumor size and, according to the doctors, there was no sign of
recurrence. It seems that we are in the favorable scenario. The patient
will be called again for follow-up in mid-2019.
Keywords: Bladder Cancer, Dynamic Model, Uncertainty Quantification,
Model Calibration, Cancer Prognosis.
1 Introduction
Bladder cancer is one of the most common malignant diseases in the urinary
system and a highly aggressive neoplasm [5, 12]. Around 80% of patients diag-
nosed with this cancer present a non invasive carcinoma that can be handled via
a Trans Urethral Resection (TUR), a surgical endoscopic procedure to remove
∗Corresponding author
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the tumor from the inner part of the bladder [9]. In this procedure, a catheter is
introduced by the urethra until arriving to the bladder. With a camera attached
to the top of the catheter, the tumor is found with a sight inspection and then
removed using a scalper. There is no need of cutting into the abdomen, and
therefore, it is considered a minor surgery.
The bladder cancer is characterized by recursiveness for more than a half
of the patients: the tumor appears again after a while and may progress to
become a muscle invasive cancer. It is then when the treatments become more
aggressive, including the removal of the bladder to avoid the spread of the cancer
to other parts of the body [14].
The prognosis of bladder cancer is not generally good and after the TUR,
the typical treatment consist of instillations of Bacillus Calmette-Guérin (BCG)
into the bladder, with the aim that the BCG stimulates the patient’s immune
response against the cancer and then, the cancer cells may be eliminated [17].
When BCG instillations are administered, the BCG cells attach to the
urothelial cells and they get internalized by the bladder cancer cells. Because
of this, the bladder cancer cells release substances such as cytokines and anti-
gen presentation, which promotes the immune cells recruitment and suppression
activity [17].
Despite the advancements in molecular biology techniques [6] and the knowl-
edge of the cancer stages and the treatments [1, 2], it is not well known the
mechanisms of bladder cancer evolution in particular patients, why and when
some of them heal and others have recurrences. In fact, the treatment protocols
have not changed in the last 25 years.
With the aim of providing some light to the problem of customizing the
evolution of bladder cancer and its treatment, here, we propose a mathematical
model to study the evolution of the bladder cancer of a patient where TURs
and the administration of BCG have been considered in the evolution. Also,
we consider in the model the immune response caused by the apparition and
growth of the tumor and the interaction of cancer cells with the immune system.
To our knowledge, only in the paper written by Bunimovich-Mendrazitsky et al.
[7], the authors introduce a model of this kind using average parameter values
obtained from several in silico patients data.
At this point, we must say that, even though the antecedent of Bunimovich-
Mendrazitsky et al. [7] has been very valuable to develop our model, we had
to design our own model. This is because our model has to be applied with
the available data of our patients, given that the available data are those the
anatomic pathologist doctors consider relevant to be analyzed in order to deter-
mine the evolution of the sickness rather than the data we could consider as nec-
essary for the model. Also, our model should describe properly the clinic prac-
tice in the Hospital Universitari i Politècnic La Fe [4] in Valencia, Spain, where
we collaborate with the doctors of the Urology Department and the Pathology
Department. Furthermore, we introduce into the model new recent findings
related to the interaction between inflammatory and tumor cells.
Thus, we are going to propose a model to describe the evolution of the
bladder cancer, to use data of a patient to determine the model parameters that
describe the known evolution and employ these calibrated model parameters to
predict the evolution of the bladder cancer in the short-term. Due to the lack of
data, we are going to perform the evolution taking into account three possible
scenarios: favorable, neutral and unfavorable.
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The paper is organized as follows. In Section 2, we introduce the data
available collected from the Hospital Universitari i Politècnic La Fe. In Section
3 we build the model describing the evolution of the tumor size and the immune
response in stages determined by the medical protocols. In Section 4, we find
the model parameter values that allow the model to describe the bladder cancer
evolution until now and we show the result of the calibration. In Section 5,
we predict the evolution of the size of the tumor and the immune system over
the next few months in three scenarios: favorable, neutral and unfavorable.
Also, we describe the patient’s follow-up actions done. Finally, we present some
conclusions of the work.
2 Available data
Typically, in the Spanish Region of Valencia, a patient goes to the family doctor
or the emergencies of the hospital when he/she starts to urinate blood (hema-
turia). Then, the patient is addressed to the urologist, who, using ultrasound
images or a cytoscopy, diagnoses if there is a tumor inside the bladder. If so,
the patient is treated by the doctors in the Urology Department. In our case,
we are working with doctors belonging to the Hospital Universitari i Politècnic
La Fe. The doctors have collected biological tissues of patients suffering pT1G3
bladder cancer, a non muscle-invasive stage of the bladder cancer. Then, the
usual protocol is
• to perform a TUR to the patient.
• After the TUR, the anatomic pathologist doctor, observes the tumor and
measures the tumor size (diameter) and the immune response in the tu-
mor microenvironment by counting the inflammatory cells (CD3, CD20,
CD56, CD68, CD138, FoxP3 and tryptase). With the collected data, the
anatomic pathologist doctor reports the urologists;
• to administer instillations of BCG;
• to perform cytologies and cystoscopies for follow-up control and revisions.
In case of recurrence, the doctors repeat the cycle described above until
the patient is completely healthy or the cancer has increased and invaded the
bladder muscle layer. In this latter case, more aggressive treatments have to be
applied.
Among the patients, we have chosen from the Hospital Universitari i Politèc-
nic La Fe database the only one with the complete medical history for our
purpose with the aim to perform a retrospective study. We are going to call
this patient Patient X, and the available data are collected and summarized in
Table 1.
The anatomic pathologist doctor, in their practise, measures the number
of inflammatory cells as the average of five countings from different parts of
the tumor microenvironment that they observe through a 40x microscopy lens.
This is what is called ”average inflammatory cells per microscopy field” (right
column in Table 1). We gather all the types of the inflammatory cells assuming
a joint effect against the tumor cells.
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Apart from the information provided in Table 1, instillation dates are also
known. BCG instillations were started the days 10/Aug/2012, 26/May/2015
and 27/Apr/2017, after each TUR. Doses introduced in the bladder consisted
of 81 ml of BCG colonies instilled once per week during six weeks.
3 Model building
To design a reliable model, we are going to take into account the available
data and their magnitudes, describing properly the clinic practice in the Hos-
pital Universitari i Politècnic La Fe, and including recent discoveries about the
interaction between tumor cells and the immune system, and facts do not con-
sidered in literature, mainly: (a) the fact that the immune system also attacks
non-infected tumor cells [13]; (b) in the interaction between tumor cells and
inflammatory cells, the tumor cells can kill inflammatory cells [10]; and (c) the
immune response is only dependent on tumor cells [11].
The model is going to be built in two stages. It is natural, because from the
tumor detection and diagnosis to the first TUR, there are only two interacting
actors: the tumor cells and the immune system. However, after the first TUR
and the application of the BCG treatment to the patient, tumor cells, infected
tumor cells, BCG and the immune system, all of them, interact. This latter
interaction will be repeated every time a new TUR is performed and BCG
administered.
3.1 Modeling the first stage
As we mentioned before, at this stage only tumor cells and inflammatory cells
interact. Then, following the units of the data collected in Table 1, we define
T (t) as the diameter of the tumor at the day t and I(t) as the average number
of inflammatory cells per microscopy field at the day t. In the following we
abbreviate it and we name I(t) as inflammatory cells.
For model building, let us consider the following assumptions:
A1 the tumor grows following the classical exponential growth difference equa-
tion, T (t+ 1) = T (t) + kT (t), where k is the growth rate;
A2 the inflammatory cells kill the tumor cells and reduce the tumor size [13];
it is modeled by the term λ2I(t)T (t) where λ2 is the killing rate;
A3 the inflammatory cells increase because of the presence of tumor cells [11].
It is modeled by the term b1T (t), where b1 is the increase rate;
A4 the encounters of inflammatory cells with the tumor cells provokes the in-
activation (death) of the inflammatory cells [10]; it is modeled by the term
λ1I(t)T (t) where λ1 is the killing rate;
A5 the natural death of the inflammatory cells is modeled by the term d1I(t)
where d1 is the death rate.
In the Figure 1 we can see how every assumption contributes to the model
building in this first stage.
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Therefore, the dynamics of the tumor growth and the inflammatory cells and
their interaction in the first stage is given by the following system of difference
equations
T (t+ 1) = T (t) + kT (t) − λ2I(t)T (t),
I(t+ 1) = I(t) − d1I(t) + b1T (t) − λ1T (t)I(t),
(1)
where the time t is in days, T (0) is the initial diameter, I(0) is the initial
average number of inflammatory cells per microscope field (see Table 1), being
t = 0 the day 01/Mar/2012.
We point out the importance of the parameter λ2 because it measures the
effectiveness of the immune system to kill tumor cells and reduce the tumor size.
Remark 3.1 At this point, it is usual to perform a dynamic analysis of the
model in order to obtain information about the studied phenomenon. Then, the









for the scenario where we reach a tumor with constant size. In this latter
scenario, T is positive if λ2b1 > λ1k. However, because of cancer cells anoma-
lous and high growth rate, if the rates λ2, b1 and λ1 have similar magnitudes
and k is much greater than them, the condition λ2b1 > λ1k will not be satisfied.
Moreover, the physicians say that situations where the tumor reaches a constant
size because of the immune system are very rare due to the aggressive grade of
the bladder tumor (grade 3) [16].
Therefore, in this case, the dynamic analysis show an unrealistic behavior
and does not provide new relevant information on the phenomenon.
3.2 Modeling the second stage
This second stage starts when the TUR removes the tumors and, after a while,
BCG treatment is administered. The tumor is still growing because, although
the doctors do their best, the complete removal is almost impossible (”seed and
soil” theory)[18]. Apart from the tumor cells and the inflammatory cells, in
this stage, BCG appears via instillations and the effect of the BCG is to infect
tumor cells to get marked facilitating the attack of the inflammatory cells in a
more aggressive way. This way, the action of the inflammatory cells is much
more effective than without BCG and this is called specific immune response
[17]. Thus, infected tumor cells have to be considered in this stage too.
Then, let us denote by B(t) the milliliters of BCG inside the bladder, b(t)
the milliliters of BCG injected in one or several doses per day t and Ti(t) as the
diameter of the tumor cells infected by BCG, at the time instant (day) t.
For model building this second stage, let us consider the following assump-
tions:
A6 when a bacillus encounters a tumor cell, the tumor cell becomes infected
and the bacillus gets attached to the tumor cell [17]. This is modeled
by the term τ2T (t)B(t) where τ2 is the infection rate. This term affects
decreasing T (t), increasing Ti(t) and decreasing B(t);
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A7 in A3, inflammatory cells increase because of tumor cells, and now, also
because the infected ones. It is modeled by the term b2Ti(t) where b2 the
apparition rate of the inflammatory cells because the infected tumor cells;
A8 the death of the inflammatory cells because the infected tumor cells [13].
This is modeled by the term τ1Ti(t)I(t) where τ1 is the death rate;
A9 the growth of inflammatory cells because of BCG [8]. This is modeled by
τ5B(t)I(t) where τ5 is the growth rate;
A10 the death of infected tumor cells and the reduction of its size because of
inflammatory cells [17]. This is modeled by τ4I(t)Ti(t) where τ4 is the
death rate;
A11 the natural disappearance of BCG by urination is modeled by the term
d2B(t), where d2 is the urination rate. According to the treatment proto-
col of the Spanish Minister of Health [3], when the BCG instillations are
introduced into the bladder, the patients urinate it about two hours after
the procedure. The BCG cells are internalized by the tumor cells [17]. If
the BCG cells that are not internalized and would stay long time in the
bladder, there could be an infection. The urination expels all the BCG
cells before they start to die.
A12 the death of BCG because the inflammatory cells attack BCG [8]. This is
modeled by τ3I(t)B(t) where τ3 is the death rate;
In the Figure 2 we can see how every assumption contributes to the model
building in this second stage.
It is important to remark that the effectiveness of the BCG treatment is
based on the fact that parameter τ4 (A10) is much greater than λ2 (A2)
because BCG infects the tumor cells and facilitates the detection and destruction
by the inflammatory cells (specific immune response). All the above model
parameters and their description have been summarized in Table 2.
Then, gathering all the above terms, the evolution of the dynamics of the
size of tumor, inflammatory cells and BCG can be modeled using the following
system of difference equations (time t in days):
T (t+ 1) = T (t) + kT (t) − λ2I(t)T (t) − τ2B(t)T (t),
I(t+ 1) = I(t) − d1I(t) + b1T (t) − λ1T (t)I(t) + b2Ti(t)
−τ1Ti(t)I(t) + τ5B(t)I(t),
Ti(t+ 1) = Ti(t) + τ2T (t)B(t) − τ4I(t)Ti(t),
B(t+ 1) = B(t) − d2B(t) − τ2T (t)B(t) − τ3I(t)B(t) + b(t).
(2)
At this point, we must say that model parameters λ2, τ4 and τ5 are going to
be variable over the stages. They are responsible of the immune response before
and after the administration of the BCG. Then, after the first BCG adminis-
tration, the immune system is highly stimulated and the values of the model
parameters λ2, τ4 and τ5 reach their highest values. If more BCG administra-
tion is necessary, the stimulation of the immune response is not as well as in
the first time and the model parameter values λ2, τ4 and τ5 use to decrease as
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the stages goes on. This is natural taking into account the behavior of the im-
mune response (sudden increase because of BCG and slow decrease) and noting
that the output returned by the model of the immune response cannot overpass
certain values in order to keep the model credibility (around 800).
4 Model calibration
Model calibration has been made in stages, because it is not a continuous process
due to the sudden extraction of the tumor with TURs. For Patient X there are
three different stages, separated by TURs:
1. the first stage starts the 01/Mar/2012 and lasts until 14/Jun/2012;
2. the second stage starts the 15/Jun/2012 and lasts until 28/Apr/2015;
3. the third stage from the 29/Apr/2015 to 14/Mar/2017.
Predictions will be made for dates after the 14/Mar/2017, considering the
instillations administered 27/Apr/2017 and during 6 weeks, once per week.
In the first stage, the model is given by the system (1). The system (2) will
be used for the second and third stage, and also for predictions.
4.1 Calibration of the first stage
Taking into account the lack of data because of the nature of its measurement
and the large number of model parameters, we have to consider the reduction
of the parameters space in order to guarantee reliable calibrations. Looking
at the data about the size of the tumor in the Table 1, considering only the
growth tumor model T (t + 1) = T (t) + kT (t) and performing a calibration of
the parameter k in the three stages, we can obtain that parameter k cannot be
greater that 0.0204. k is the growth tumor rate and it is much greater than
the usual growth rates for healthy cells, by definition of cancer. Therefore, the
parameters related with the growth and death of cells, b1, b2, d1, d2, should be
smaller than k. Similar reasoning can be done for the remainder parameters
insofar they are involved in the growth or death of the cells and BCG.
Furthermore, Table 1 shows small changes in the inflammatory cells per field
in second and third TURs, where the immune system has been changed because
of the instillations of BCG. We are going to assume the same behavior before
the first TUR, what means that initially, we expect around 260 inflammatory
cells the 01/Mar/2012.
As we mentioned above, although the doctors do their best, the bladder is
not completely free of tumor cells after the TUR. Therefore, we are going to
consider that the diameter of the tumor after a TUR will be determined by
the model after the calibration. This size is small enough to be considered the
bladder gets ”clean” after a TUR and permits the tumor keep growing, which
we know that happens because of recurrences.
Now, in order to find the model parameters that make the model to be as
close as possible to the data of Table 1 in the corresponding time instants, we
define the following fitting function F1:
INPUT: Model parameter values (k, λ1, λ2, d1, b1);
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Step 1. Substitute the model parameter values into the model (1);
Step 2. Run the model and retrieve the model output for tumor size and av-
erage inflammatory cells per field in the same time instants as those in
Table 1;
Step 3. Calculate the root mean square between the model output retrieved in
Step 2 and the data in Table 1.
For model calibration, we minimize the function F1 in this stage using the
rPSO algorithm [15], and the model parameter values are given in Table 3.
The calibration procedure allowed us to determine more precisely the initial
conditions T (0) = 4.64 mm and I(0) = 265.
4.2 Calibration of the remainder stages
Once the first stage has been calibrated, the parameters k, λ1, d1, b1 are known
and only the remainder parameters have to be calibrated in the second stage. As
we mentioned above, the model parameters λ2, τ4 and τ5 are going to be variable
over the stages, meanwhile the remainder model parameters will remain constant
over the stages. Now, for the calibration in the second stage, we propose the
following fitting function F2:
INPUT: Model parameter values (λ2, d2, b2, τ1, τ2, τ3, τ4, τ5). The model pa-
rameters k, λ1, d1 and b1 are those with the values given in Table 3;
Step 1. Substitute the model parameter values into the model (2);
Step 2. Run the model and retrieve the model output for tumor size and in-
flammatory cells per field in the same time instants as those in Table
1;
Step 3. Calculate the root mean square between the model output retrieved in
Step 2 and the data in Table 1.
For model calibration in the second stage, we minimize the function F2 using
the rPSO algorithm [15], and the model parameter values are given in Table 4.
Now, for model calibration in the third stage, the model parameter values
k, λ1, d1, b1, d2, b2, τ1, τ2, τ3 have been calculated and only λ2, τ4, τ5 have to be
calibrated again, using the fitting function F2 where, now, the unknown model
parameters are only λ2, τ4, τ5. Then, using the rPSO algorithm [15], the cali-
brated model parameters are given in Table 5. It can be seen that the model
parameter values satisfy the restrictions stated through this section.
In Figure 3, we can see the result of the calibration, that is, the evolution of
the tumor size and the immune system development. In the lower figure (tumor
size) the sudden drops correspond to TURs, when the tumor is removed. Then,
it starts to grow again. Respect to the upper figure (immune response), we can
see a quick increasing after TUR corresponding to the BCG instillations and
how they influence the immune response. The saw teeth appearing when BCG
is administered are due to the weekly doses, once per week, of BCG instilled.
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5 Predictions and patient’s follow-up
Due to the uncertainty in the future evolution, in order to predict the dynamics
of the bladder cancer for Patient X, three different scenarios have been consid-
ered. In the favourable scenario the response of the immune system takes the
maximum possible values that allow the reliability of the values corresponding
to the immune system response, usually less than the values as after the first
TUR (second stage). The neutral scenario consists of the same response of the
immune system as in the third stage, that is to say, the immune system response
remains constant. The unfavourable scenario is based on the fact that the re-
sponse of the immune system decreases in the same proportion as it decreased
from the second to the third stage. In Table 6 the values of the parameters
corresponding to the described scenarios are shown.
In Figures 4, 5 and 6, the prediction in the different scenarios are shown. The
prediction starts in the dashed black vertical line. In the favourable scenario,
the BCG treatment is successful and the tumor does not seem to grow in the
prediction time interval until 15/Sep/2018, after the third instillation treatment
is finished. In the neutral scenario, bladder cancer recurrence with a tumor of
size 7-8 mm is predicted for the 15/Sep/2018. In the unfavourable scenario,
bladder cancer recurrence with a tumor of size 40-42 mm is predicted for the
15/Sep/2018.
5.1 Patient’s follow-up
Patient X was called for a revision the 15/Mar/2018 (10 months after the last
administration of BCG) and, after a cystoscopy, the doctors did not find any
trace of bladder cancer. Then, she was called again the 6/Jun/2018 (13 months
after the last administration of BCG) where the cytoscopy was inconclusive.
A week later, a molecular test called XPERT Bladder Cancer Monitor was
performed with negative results.
The model in the unfavorable and neutral scenarios, predicts tumor of sizes
9.2 mm and 2.4 mm for 6/Jun/2018. Therefore, the unfavorable scenario is
discarded for Patient X. The neutral scenario gives a tumor size not visible in
a cytoscopy, although the XPERT Bladder Cancer Monitor test could detect.
The following revision was 10/Sep/2018 (16 months after the last admin-
istration of BCG). According to the doctors, there was no sign of recurrence.
Thus, it seems that Patient X is in the favorable scenario. Anyway, the pa-
tient will be called again for follow-up in mid-2019, where the favorable scenario
predicts the apparition of new tumors.
6 Conclusion
In this paper, we build a dynamic mathematical model to describe the evolution
of the size of a bladder tumor and the immune system response in a given
patient. The model is calibrated in several stages determined by the TURs
included in the hospital protocol and the obtained parameters allow us to give
a prediction about the tumor growth and the immune system response over the
next few months in three scenarios: favorable, neutral and unfavorable. To our
knowledge, this is the first approach of this type applying the model to a given
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patient and the results seem to be promising, insofar the doctors of the Hospital
Universitari i Politècnic La Fe have scheduled patient’s revisions following the
predictions given by the model.
Some predictions have been made and they are going to be checked with
programmed patient’s revisions. Some scenarios have been discarded, but others
have to be examined in the near future. In fact, the Patient X will be called in
mid-2019 to measure the size of the tumor, if it exists.
This is a working model, built ad-hoc to be adapted to the data provided by
the Hospital Universitari i Politècnic La Fe and applied to a particular patient.
If this experience with Patient X gives us reliable results, the model will be
calibrated for more patients using more data in order to predict the future
evolution of this disease in each one of them. In fact, the doctors are working
on obtaining more information and data about the patient’s evolution to feed
the model. Moreover, improvements of the model are also contemplated.
Thus, we will be able to check the validity of our approach, performing
better and more accurate predictions, giving tools to the doctors to administer
treatments, to schedule the patient’s revisions and, in the future, to determine
the best strategies to improve the patient’s health avoiding tumor recurrences,
if possible, with an important saving of time and resources.
Furthermore, the model and the obtained results indicate us that it would
be interesting to administer the BCG as soon as possible in order to improve
the effect against the remainders of the tumor after the TUR. We suggested
this to the doctors, nevertheless, this kind of changes involve variations in the
hospital’s protocol and it takes time and bureaucracy.
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Figure 1: Modeling. First stage. In this figure we can see the contribution of
the model terms of every assumption to the model building.
Figure 2: Modeling. Second stage. In this figure we can see the contribution of










































Figure 3: Here we show the graphs with the evolution of the immune response
(upper) and the tumor size (lower) with the parameters obtained in the model
calibration. The points represent the available data in Table 1. The sudden
drops in the lower graph correspond to the TURs, when tumors are removed.
The sudden increasings in the upper graph correspond to the administration of










































Figure 4: Favorable scenario. The prediction appears on the right of the dashed
vertical black line. It can be seen that the tumor does not seem to grow in the
prediction time interval, that is, it seems that the BCG treatment will be able
to kill the remainder tumor cells. However, after two years, we must say that










































Figure 5: Neutral scenario. The prediction appears on the right of the dashed
vertical black line. After a while, the tumor grows again and a recurrence is
expected, reaching the size of 7-8 mm in the middle of September 2018 (16












































Figure 6: Unfavourable scenario. The prediction appears on the right of the
dashed vertical black line. Here, the effect of BCG is almost inexistent and the
tumor grows quickly reaching the size of 40-42 mm in the middle of September




Date Medical Diameter of Avg inflammatory
procedure the tumor cells per field
01/Mar/2012 Ultrasound 3-5 mm -
14/Jun/2012 TUR 25 mm 260
15/Feb/2015 Cystoscopy 1-2 mm -
28/Apr/2015 TUR 5 mm 515
30/Jan/2017 Cystoscopy 20 mm -
14/Mar/2017 TUR 30-35 mm 508
Table 1: Data corresponding to Patient X, who was diagnosed in the first of
March 2012. Since then, the Patient X has suffered three TURs and has been
treated with three BCG instillation sessions, each one after each TUR. The last
column shows the average number of inflammatory cells per microscopy field
counted by the pathologist after every TUR.
Parameter Units Description Term
k unitless Tumor size growing rate. kT (t)
λ1 mm
−1 Inflammatory cells death rate because −λ1I(t)T (t)
of uninfected tumor cells.
λ2 cells
−1 Tumor cell death rate because −λ2I(t)T (t)
of inflammatory cells (effectiveness).
d1 unitless Inflammatory cells natural death rate. −d1I(t)
b1 cells × mm−1 Production rate of inflammatory cells b1T (t)
because of the presence of the tumor cells.
d2 unitless BCG natural disappearance rate by −d2B(t)
urination.
b2 cells × mm−1 Production rate of inflammatory cells b2Ti(t)
because of the presence of the infected
tumor cells.
τ1 mm
−1 Death rate of inflammatory cells because −τ1Ti(t)I(t)
the infected tumor cells.
τ2 ml
−1 Infection rate of tumor cells and its effect τ2T (t)B(t)
on the reduction of the BCG.
τ3 cells
−1 BCG death rate because of inflammatory −τ3I(t)Ti(t)
cells.
τ4 cells
−1 Infected tumor cells death rate because −τ4B(t)I(t)
of inflammatory cells (effectiveness
of BCG).
τ5 ml
−1 Inflammatory cells growth rate because τ5B(t)IE(t)
of BCG.
Table 2: Model parameters, units, description and modeling term. Positive
terms mean growth of cells and negative terms mean death or removal of cells.
Above the horizontal line, the parameters involved in the first stage. Below the




λ1 8.1186 × 10−6
λ2 6.8426 × 10−6
d1 1.6 × 10−4
b1 9.08 × 10−5
Table 3: Model parameter values calibrated for Patient X in the first stage, until
the first TUR. The time step is daily.
Parameters Value
λ2 2.393 × 10−5
d2 0.8864
b2 5.89 × 10−3
τ1 2.8689 × 10−5
τ2 2.1 × 10−3
τ3 2.207 × 10−4
τ4 8.59 × 10−3
τ5 1.85 × 10−3
Table 4: Model parameter values calibrated for Patient X in the second stage,
after the first TUR until the second TUR. The time step is daily.
Parameters Value
λ2 1.205 × 10−5
τ4 3.9132 × 10−4
τ5 2.43878 × 10−4
Table 5: Model parameter values calibrated for Patient X in the third stage,
after the second TUR. The time step is daily.
Parameters Favourable Neutral Unfavourable
scenario scenario scenario
λ2 2.393 × 10−5 1.205 × 10−5 5.9822 × 10−6
τ5 8.59 × 10−3 3.9132 × 10−4 3.7349 × 10−4
τ6 3.692 × 10−4 2.4387 × 10−4 2.1166 × 10−4
Tumor size 15/Sep/2018 Non detectable 7-8 mm 40-42 mm
Table 6: Model parameter values in the three different scenarios: favorable,
neutral and unfavorable. Expected tumor size the September 15th, 2018 (16
months after the last administration of BCG) in the three scenarios. The time
step is daily.
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